GcMAF: Difference between revisions
CSV import |
CSV import |
||
| Line 28: | Line 28: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
{{pharmacology-stub}} | {{pharmacology-stub}} | ||
{{No image}} | |||
Revision as of 18:22, 10 February 2025
GcMAF (Gc Protein-derived Macrophage Activating Factor) is a protein produced by modification of vitamin D-binding protein. Biochemically, GcMAF results from sequential deglycosylation of the vitamin D-binding protein (the Gc protein), which is naturally promoted by lymphocytes (B and T cells).
Biochemistry
The native Gc protein (also known as vitamin D3-binding protein) is a glycoprotein that contains a single sugar chain moiety. The sugar moiety of the native Gc protein is composed of three sugars, galactose, N-acetylgalactosamine, and sialic acid, the latter of which is critical for the conversion of Gc protein to GcMAF.
Function
GcMAF is a potent stimulator of the immune system. It plays a role in the activation of macrophages, a type of white blood cell that engulfs and digests cellular debris, foreign substances, microbes, and cancer cells in a process called phagocytosis.
Clinical Significance
GcMAF has been studied for its potential use in the treatment of various diseases, including cancer, HIV, and autism. However, the scientific evidence supporting these uses is currently limited and further research is needed.
Controversy
The use of GcMAF has been controversial due to lack of robust clinical evidence and regulatory issues. In some countries, GcMAF products have been banned due to safety concerns.
See Also
References
<references />
